Cargando…

Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study

INTRODUCTION: Hypoglycemic drugs affect the bone quality and the risk of fractures in patients with type 2 diabetes mellitus (T2DM). We aimed to investigate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and insulin on bone mineral density (BMD) in T2DM. METHODS: In this single-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Ting-ting, Li, Hui-qin, Jiang, Lan-lan, Wang, Hui-ying, Luo, Meng-hui, Su, Xiao-fei, Ma, Jian-hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464416/ https://www.ncbi.nlm.nih.gov/pubmed/34580638 http://dx.doi.org/10.1155/2021/3361309

Ejemplares similares

Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
por: Lim, Soo, et al.
Publicado: (2017)

Changes in the Bone Mineral Density of Femur Neck and Total Hip Over a 52-Week Treatment with Lobeglitazone
por: Lee, Da Young, et al.
Publicado: (2017)

Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
por: Ishihara, Hisamitsu, et al.
Publicado: (2018)

An overview of the once‐weekly GLP‐1 receptor agonists from the pharmacist’s perspective
por: Patel, Dhiren
Publicado: (2020)

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
por: Nauck, Michael A., et al.
Publicado: (2015)

Diabetes mellitus accelerates the progression of osteoarthritis in streptozotocin-induced diabetic mice by deteriorating bone microarchitecture, bone mineral composition, and bone strength of subchondral bone
por: Wang, Hua-Jun, et al.
Publicado: (2021)

Lean mass and peak bone mineral density
por: Nguyen, Huy G., et al.
Publicado: (2020)

Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
por: Trujillo, Jennifer
Publicado: (2020)

The immune factors have complex causal regulation effects on bone mineral density
por: Cao, Rong-Rong, et al.
Publicado: (2022)

Association of body composition with bone mineral density and fractures in Chinese male type 2 diabetes mellitus
por: Meng, Chuchen, et al.
Publicado: (2022)

The metabolic score of insulin resistance is positively correlated with bone mineral density in postmenopausal patients with type 2 diabetes mellitus
por: Gu, Peng, et al.
Publicado: (2023)

Metabolomic profiles associated with bone mineral density in US Caucasian women
por: Zhao, Qi, et al.
Publicado: (2018)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Association between Serum Uric Acid Levels and Bone Mineral Density in Taiwanese Elderly Population
por: Chung, Pei-Ting, et al.
Publicado: (2023)

The GLP‐1/GIP dual‐receptor agonist DA5‐CH inhibits the NF‐κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP‐1 single‐receptor agonist NLY01
por: Lv, MiaoJun, et al.
Publicado: (2021)

Association between parity and bone mineral density in postmenopausal women
por: Yang, Yimei, et al.
Publicado: (2022)

Effect of 2–6 weeks of systemic steroids on bone mineral density in children
por: Kuniyil, Athira, et al.
Publicado: (2021)

A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Kayaniyil, Sheena, et al.
Publicado: (2016)

The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review
por: Daniilopoulou, Ioanna, et al.
Publicado: (2022)

Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis
por: Song, Nazi, et al.
Publicado: (2022)

Assessment of Low Bone Mineral Density in Untreated Patients with Takayasu's Arteritis
por: Mo, Lingfei, et al.
Publicado: (2021)

Bone mineral density evaluation of patients with type 2 diabetes mellitus
por: Adil, Camli, et al.
Publicado: (2015)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Association between age at menarche and bone mineral density in postmenopausal women
por: Yang, Yimei, et al.
Publicado: (2023)

Spine trabecular bone scores and bone mineral density of postmenopausal Taiwanese women
por: Huang, Mei-Lan, et al.
Publicado: (2022)

Analysis of Bone Mineral Density/Content of Paratroopers and Hoopsters
por: Luo, Yixue, et al.
Publicado: (2018)

Comprehensive Analysis of the Genetic and Epigenetic Mechanisms of Osteoporosis and Bone Mineral Density
por: Dong, Hui, et al.
Publicado: (2020)

Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Goldman, Jennifer D.
Publicado: (2020)

Energy Balance in Hypothalamic Obesity in Response to Treatment with a Once-Weekly GLP-1 Receptor Agonist
por: Shoemaker, Ashley H., et al.
Publicado: (2022)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Relationships between serum Omentin-1 levels and bone mineral density in older men with osteoporosis
por: Yang, Li, et al.
Publicado: (2016)

Low Bone Mineral Density in Chinese Adults with Nonalcoholic Fatty Liver Disease
por: Cui, Ran, et al.
Publicado: (2013)

Quantification of the relative contribution of estrogen to bone mineral density in men and women
por: Ho-Pham, Lan T, et al.
Publicado: (2013)

Effect of insulin resistance on gonadotropin and bone mineral density in nondiabetic postmenopausal women
por: Ye, Shujin, et al.
Publicado: (2023)

Increased bone mineral density in postmenopausal women with type 2 diabetes mellitus
por: Hadzibegovic, Irzal, et al.
Publicado: (2008)

Prolactin is associated with bone mineral density in subjects with type 2 diabetes mellitus
por: Chen, Jia, et al.
Publicado: (2022)

Erratum to “Analysis of Bone Mineral Density/Content of Paratroopers and Hoopsters”
por: Yixue, Luo, et al.
Publicado: (2021)

Evaluation of bone mineral density in patients with gestational diabetes mellitus by ultrasonic bone mineral density measurement combined with Vitamin-D deficiency and analysis of influencing factors
por: Han, Lulu, et al.
Publicado: (2022)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

Association between lumbar endplate damage and bone mineral density in patients with degenerative disc disease
por: Huang, Shan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bp40tbtthcaq1tprtvlk6ktk75